Study Evaluating the Long-term Safety and Efficacy of VX-445 Combination Therapy
Status:
Active, not recruiting
Trial end date:
2022-08-01
Target enrollment:
Participant gender:
Summary
This study will evaluate the long-term safety, efficacy, and pharmacodynamics of elexacaftor
(ELX, VX-445) in triple combination (TC) with tezacaftor (TEZ) and ivacaftor (IVA) in
subjects with cystic fibrosis (CF) who are heterozygous for the F508del mutation and a gating
or residual function mutation (F/G and F/RF genotypes).